Psilocybin | Jotup

HYTN Clears PIC/S GMP Audit, Primed for Global Expansion

Retrieved on:

Monday, March 4, 2024

TGA, Growth, PIC/S, GMP, Psilocybin, Therapeutic Goods Administration, Certification, THC, Cannabis, Drink, Partnership

The positive outcome of the audit has set the stage for the subsequent issuance of formal GMP certification allowing the company to access international medical markets.

Key Points:

The positive outcome of the audit has set the stage for the subsequent issuance of formal GMP certification allowing the company to access international medical markets.
The GMP audit conducted by the TGA was performed in accordance with the standards of the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme ("PIC/S").
Once issued, GMP certification under the PIC/S framework allows HYTN to engage with international medical markets that recognize the PIC/S standard, through established reciprocal agreements.
This step also allows us to elevate our existing systems, bringing our current and future product offerings into compliance with GMP standards.”

Pervasip Announces Financial Results for Fiscal Year 2023

Retrieved on:

Thursday, February 29, 2024

Financial audit, Biomass, PVSP, Net income, Psilocybin, Cannabinol, Bank statement, Cryptocurrency

SEATTLE, WA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Pervasip Corp. (OTCPK: PVSP) (“Pervasip” or the “Company”), a developer of companies and technologies in high value emerging markets, today announced the filing of its unaudited financial statements for its fiscal years ended November 30, 2023.

Key Points:

SEATTLE, WA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Pervasip Corp. (OTCPK: PVSP) (“Pervasip” or the “Company”), a developer of companies and technologies in high value emerging markets, today announced the filing of its unaudited financial statements for its fiscal years ended November 30, 2023.
Operating Loss for the year ending November 30, 2023 totaled ($460,037), compared to an operating loss of $2,422,916 during the same period in 2022.
Cashflow for the year ending November 30, 2023 totaled $409,507, compared to negative cashflow of ($798,033) during the same period in 2022.
Pervasip additionally owns 5% of KRTL Biotech, Inc., a developer of biotechnologies with a focus on pharmaceutical applications of cannabinol and psilocybin.

Beckley Academy Publishes First Open-Source Learning Framework to Advance Psychedelic-Assisted Therapy Training Standards

Retrieved on:

Tuesday, February 27, 2024

Psilocybin, MAPS, APPA, Risk, MDMA, Business, Organization, Ketamine, PAT, Publication, Research, Nursing

NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Beckley Academy , the learning studio that prepares and trains practitioners to provide psychedelic-assisted therapy (PAT) with Ketamine, Psilocybin, and MDMA, announced today the open-source publication of its research: A Psychedelic-Assisted Therapy Learning Framework .

Key Points:

NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Beckley Academy , the learning studio that prepares and trains practitioners to provide psychedelic-assisted therapy (PAT) with Ketamine, Psilocybin, and MDMA, announced today the open-source publication of its research: A Psychedelic-Assisted Therapy Learning Framework .
This industry-first learning framework will serve as a much-needed foundation to advance national training standards for clinicians to provide ethical and effective psychedelic-assisted therapy.
Currently, no national training standards or certifications exist for psychedelic practitioners, though many organizations have independently created training programs, practice guidelines, and codes of ethics.
Beckley Academy co-founding team members Deborah Gardner and Shirelle Noble recognized the opportunity to analyze existing publications and create a unified framework.

BRIGHT GREEN CORPORATION GAINS MOMENTUM FOR THEIR “DRUGS MADE IN AMERICA” PLATFORM WITH APPROVAL FOR THE RESEARCH, PRODUCTION AND MANUFACTURING OF ALL SCHEDULE I AND SCHEDULE II PLANT-BASED DRUGS

Retrieved on:

Thursday, February 22, 2024

Psilocybin, Cocaine, Medicine, Research, API, Opium, Active ingredient, DEA, Federation, Ground substance, Policy, Uncertainty, Mescaline, Partnership, Drug

GRANTS, N.M., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (Nasdaq: BGXX) (“Bright Green” or the “Company”) company announced today that final approval has been received from the New Mexico Board of Pharmacy and the DEA for unique licensing that allows Bright Green to register, license, and authorize Schedule I and Schedule II plant-based drugs and Active Pharmaceutical Ingredients (APIs) for research, production, and manufacturing purposes. Schedule I Substances include Psilocybin, psilocybin, mescaline, peyote, ibogaine Schedule II Substances: Opium, poppy straw, raw opium, opium extracts, powdered opium, granulated opium, tincture of opium, opium fluid extracts, opium straw concentrates, pending: erythroxylon coca (cocaine)

Key Points:

Achieving this substantial approval allows Bright Green to bring their deep expertise to these issues to help propel our Drugs Made in America movement forward.
The research will be conducted the Company’s C2 team in Albuquerque, New Mexico, and the reshoring of production and manufacturing to the U.S. will take place at the company’s Grants, New Mexico facility.
Medical plants will be produced in climate-controlled glass greenhouses engineered to ensure quality and predictability, laying a roadmap for guaranteed supply contracts with both federal government entities and other pharmaceutical interests.
Bright Green expects to be the first company in almost 100 years to produce, manufacture and supply API for Schedule I and Schedule II controlled substances and to deliver on contracts of this type.

SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds

Retrieved on:

Tuesday, February 20, 2024

Therapy, Central nervous system, DMT, LSD, TEL, Patent, Patent Cooperation Treaty, Psilocybin, PEA, CWY, Disorder, Lysergic acid diethylamide

The three patent applications refer to novel proprietary combinations of lysergic acid diethylamide (LSD), psilocybin, N,N-dimethyltryptamine (DMT) and Palmitoylethanolamide (PEA), the active ingredient of SciSparc's proprietary CannAmide™.

Key Points:

The three patent applications refer to novel proprietary combinations of lysergic acid diethylamide (LSD), psilocybin, N,N-dimethyltryptamine (DMT) and Palmitoylethanolamide (PEA), the active ingredient of SciSparc's proprietary CannAmide™.
These applications were previously filed by Clearmind as provisional patent applications with the United States Patent and Trademark Office.
"We are pleased to continue our ongoing collaboration with Clearmind by expanding the intellectual property portfolio, which is an important asset," said SciSparc’s Chief Executive Officer, Oz Adler.
"We believe in the added value that CannAmide™ can offer when combined with various psychedelic compounds that are known for their therapeutics advantages."

Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds

Retrieved on:

Tuesday, February 20, 2024

Therapy, Central nervous system, DMT, LSD, PCT, Patent Cooperation Treaty, Psilocybin, PEA, Patent, CWY, IP, Lysergic acid diethylamide, Research, Pharmaceutical industry

The three patent applications refer to novel proprietary combinations of lysergic acid diethylamide (LSD), psilocybin, N,N-dimethyltryptamine (DMT) and SciSparc's Palmitoylethanolamide (PEA), the active ingredient of SciSparc' proprietary CannAmide™.

Key Points:

The three patent applications refer to novel proprietary combinations of lysergic acid diethylamide (LSD), psilocybin, N,N-dimethyltryptamine (DMT) and SciSparc's Palmitoylethanolamide (PEA), the active ingredient of SciSparc' proprietary CannAmide™.
"Clearmind continues to be at the forefront of the psychedelic market with one of the largest IP portfolios in the industry.
The PCT makes it possible for us to seek patent protection for our proprietary compounds in a large number of countries simultaneously which strengthens our IP portfolio.
The latest patent applications build upon Clearmind’s broad IP protection in the psychedelic space, which now includes 27 granted patents and 24 pending patent applications across 15 patent families, nine of which have been granted in major jurisdictions such as the US, Europe, China, and India.

Psychedelics set to be the revolutionary treatments in pscyhiatry- Thelansis Knowledge Partners

Retrieved on:

Thursday, February 22, 2024

Availability of psychedelic(s) with few administrations in a year and offering high remission rate could change the treatment pathway for these patients."

Key Points:

Availability of psychedelic(s) with few administrations in a year and offering high remission rate could change the treatment pathway for these patients."
According to an interviewed U.S.-based neurologist by Thelansis – "We desperately need disease-modifying treatments for many neurodegenerative conditions.
As psychedelics would be beneficial for treatment-nonresponders or severe patients, the commercial opportunities are multiple for in-pipeline psychedelic therapies.
What is the probable opportunity for Psychedelics (e.g., psilocybin, MDMA) to address the unmet needs of other TAs?

Psychedelics set to be the revolutionary treatments in pscyhiatry - Thelansis Knowledge Partners

Retrieved on:

Thursday, February 22, 2024

Availability of psychedelic(s) with few administrations in a year and offering high remission rate could change the treatment pathway for these patients."

Key Points:

Availability of psychedelic(s) with few administrations in a year and offering high remission rate could change the treatment pathway for these patients."
According to an interviewed U.S.-based neurologist by Thelansis – "We desperately need disease-modifying treatments for many neurodegenerative conditions.
As psychedelics would be beneficial for treatment-nonresponders or severe patients, the commercial opportunities are multiple for in-pipeline psychedelic therapies.
What is the probable opportunity for Psychedelics (e.g., psilocybin, MDMA) to address the unmet needs of other TAs?

MycoMeditations Surveys Show Lasting Benefits of Psilocybin Therapy for Major Depression and Anxiety Disorders

Retrieved on:

Tuesday, February 20, 2024

Psilocybin, GAD-7, Social anxiety, SAD, Mental health, Multimedia, PHQ-9, Treatment, Post-traumatic stress disorder, GAD, Anxiety, Generalized anxiety disorder, Social anxiety disorder, Major depressive disorder, Clinical trial, PTSD, MDD, Comment, Research

TREASURE BEACH, Jamaica, Feb. 20, 2024 /PRNewswire-PRWeb/ -- MycoMeditations, a pioneer in legal psilocybin-assisted therapy retreats, today announced the results of two years of longitudinal (long-term) client surveys exploring the impact of its psilocybin retreats on individuals suffering with Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), and Social Anxiety Disorder (SAD). The findings complement MycoMeditations' previously released surveys focused on Post-Traumatic Stress Disorder (PTSD).

Key Points:

The findings complement MycoMeditations' previously released surveys focused on Post-Traumatic Stress Disorder (PTSD).
MycoMeditations employed the PHQ-9, GAD-7, and SM-SAD-Adult questionnaires to measure self-reported symptom severity and long-term outcomes across MDD, GAD, and SAD, respectively.
Clinically significant improvements were maintained for one year following retreat for each Major Depressive Disorder, Generalized Anxiety, and Social Anxiety, suggesting possible long-term efficacy of psilocybin-assisted therapy.
The data suggests the viability of multiple psilocybin treatments in a short period of time when coupled with therapy, as MycoMeditations retreats are 7-nights with 3 psilocybin sessions on alternating days.

Using ‘trip killers’ to cut short bad drug trips is potentially dangerous

Retrieved on:

Wednesday, February 14, 2024

As interest in psychedelics has grown, so has interest in ways to end a bad trip.

Key Points:

As interest in psychedelics has grown, so has interest in ways to end a bad trip.
Recent research reveals that people are giving potentially dangerous advice on social media on how to stop a trip that is less than pleasurable.
One of the earliest descriptions of a psychedelic experience in western literature can be found in Aldous Huxley’s 1953 book The Doors of Perception.
Research shows that if someone is in a bad mood or depressed then they are more likely to have a bad trip, as are people who take too high a dose.

Trip killers

Few clinical studies have examined trip killers, but one has found that ketanserin – a drug used to treat high blood pressure – reverses the psychedelic effects of LSD.
A recent article in the Emergency Medical Journal analysed posts on Reddit about trip killers.
Trip killers were discussed most often for LSD (235 posts), magic mushrooms (143 posts) and MDMA (21 posts).

Receptor blocking

To kill a trip then, one simply has to give the drug user another drug that blocks (rather than activates) the 5-HT2A receptor.
Many prescription drugs can do this and they tend to be antipsychotic drugs.
Quetiapine from the list above is one popular example, while another antipsychotic, olanzapine, was mentioned in 14 posts in that study.
Similarly, the atypical antidepressants trazodone and mirtazapine also block the 5-HT2A receptor.

Colin Davidson has previously received funding from the National Institute on Drug Abuse (NIH, USA) and the European Community for projects related to stimulant drug abuse and novel psychoactive compounds respectively. He is currently a paid consultant with the Defence Science Technology Laboratory (MOD) working on new psychoactive compounds.